NCT05841381View on ClinicalTrials.gov

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

876

Participants

Timeline

Start Date

May 6, 2023

Primary Completion Date

May 6, 2028

Study Completion Date

May 6, 2033

Conditions
Breast Cancer
Interventions
DRUG

Pyrotinib

pyrotinib: 400mg orally daily for 1 year

DRUG

Trastuzumab

8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles

DRUG

Paclitaxel

80mg/m2 per week for a total of 12 weeks

All Listed Sponsors
lead

Fudan University

OTHER

NCT05841381 - Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | Biotech Hunter | Biotech Hunter